Tesamorelin 

No.1 Peptide for Adipose tissue  & Bone Health

Synthetic, 44-amino acid peptide analog of Growth Hormone-Releasing Hormone (GHRH). Its sequence is a modification of the endogenous human GHRH (1-44) amide, with a single amino acid substitution (Tyr(1) to D-Ala) and the addition of a trans-3-hexenoic acid group. These modifications were engineered to increase metabolic stability and prolong its half-life in circulation, thereby enhancing its biological activity and duration of action in research models.

• Pituitary Activation
• Pulsatile GH Secretion: This stimulation results in the synthesis and release of endogenous Growth Hormone (GH) in a physiological, pulsatile pattern.

• Hepatic IGF-1 Production: The released GH acts on hepatocytes to stimulate the production of Insulin-like Growth Factor 1 (IGF-1), the primary mediator of GH’s anabolic and metabolic effects.

• Primary Research Target – Visceral Fat: A key area of investigation is its disproportionate effect on visceral adipose tissue (VAT). Research suggests that the restored GH/IGF-1 axis:

Enhances Lipolysis: Increases hormone-sensitive lipase (HSL) activity in adipocytes.

Reduces Lipogenesis: Inhibits the activity of lipoprotein lipase (LPL), reducing triglyceride storage.

Promotes Fatty Acid Oxidation: These effects are particularly pronounced in visceral fat depots, which are highly sensitive to GH action due to a higher density of GH receptors and greater metabolic activity compared to subcutaneous fat.